Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Cytopenias and infectious complications following CD19-directed CAR-T cell therapy in patients with B-ALL: A single-center retrospective analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

FIFilip IonescuVJVaishnavi JayakumarCTCorey Tesdahl

Discussion

Loading...

Member takes

Overview

Retrospective analysis found high rates of cytopenias and infections post CAR-T therapy in B-ALL, suggesting need for better risk stratification.

Key Points

  • Severe infections occurred in one-third of patients following CD19-directed CAR-T cell therapy, contributing to early and late mortality.
  • Cytopenias included Grade ≥3 anemia and neutropenia in 24% and 8.2% of patients by Day 30, respectively.
  • Retrospective analysis evaluated cytopenias and infections among 53 patients treated between 2018 and 2025.
  • Hypogammaglobulinemia significantly associated with severe infections, highlighting potential need for prophylactic IVIG.

Cite This Study

Ionescu et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236dea4https://doi.org/10.1182/blood-2025-1580
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL2025 · 5 citations
  2. 2Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy2025
  3. 3CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia2025 · 4 citations
  4. 4Prevalence and mortality of infections following CAR T-cell therapy in children, adolescents, and young adults: A systematic review and meta-analysis2025
  5. 5Burden and outcomes of CAR T-cell therapy toxicities in DLBCL, multiple myeloma, and B-ALL: A nationwide analysis2025